Anil Potti‘s retraction count is now eight with the withdrawal of a 2008 study in the Journal of the American Medical Association (JAMA). Here’s the notice, which appeared online in JAMA sometime yesterday:
“Neither snow nor rain nor heat nor gloom of night” keeps U.S. mail carriers from delivering your letters and packages, and neither seven retractions, nor being forced to resign, nor malpractice settlements (and an ongoing case) keeps former Duke oncologist Anil Potti from publishing papers. Potti’s latest effort, “A Pathway-Based Approach to Identify Molecular Biomarkers in … Continue reading Seven retractions, a resignation, and lawsuit settlements haven’t stopped Anil Potti from publishing
There are a few new developments in the case of Anil Potti, the former Duke oncologist who resigned amidst an investigation into clinical trials he was running — and has been forced to retract seven papers, at last count. Over the weekend, The Cancer Letter, which has been out front on this case, noted that … Continue reading Anil Potti reprimanded by North Carolina state medical board, as lawsuit settlements surface
The Proceedings of the National Academy of Sciences (PNAS) has published the seventh retraction for former Duke researcher Anil Potti, who now faces a lawsuit in the midst of an ongoing investigation into his work: Retraction for “A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities,” by Katherine S. Garman, … Continue reading New in PNAS: Potti retraction number seven, and a Potti correction
Anil Potti and his former Duke colleagues have retracted a sixth paper, this one in PLoS ONE. According to the retraction notice for “An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer,” the withdrawal was prompted by the retraction of a Nature Medicine paper that formed the basis of the … Continue reading Potti retraction tally grows to six with a withdrawal in PLoS ONE, and will likely end up near a dozen
From the “not terribly surprising” department: Eight patients — or their estates — who enrolled in clinical trials at Duke overseen by Anil Potti and colleagues have sued the university. The 90-page lawsuit, which names Duke, Potti, Potti’s boss Joseph Nevins, CancerGuide Diagnostics (in which Potti and Nevins had an interest), among others, does a thorough job of documenting … Continue reading Duke sued over Potti case
Anil Potti, the former cancer researcher whose work has become the subject of intense scrutiny that has already led to the retraction of five papers, didn’t tell the Journal of the American Medical Association (JAMA) about two very relevant corporate relationships he had when he published papers there, Retraction Watch has learned. JAMA has published two papers by … Continue reading Anil Potti failed to disclose corporate ties in yet-to-be-retracted JAMA papers
The list of papers retracted by former Duke oncologist Anil Potti has grown to five. The notice, from Blood:
Anil Potti, the oncologist who has been forced to retract four papers because of results that could not be reproduced, and resigned last fall from Duke, has a new job. He’s joined the Coastal Cancer Center, an oncology practice with four offices in South Carolina and one in North Carolina. The Duke Fact Checker was … Continue reading Anil Potti resurfaces at South Carolina cancer center
For those Retraction Watch readers who have been following the case of Anil Potti — who has now retracted four papers — Keith Baggerly’s name will likely be familiar. Baggerly is the bioinformatician at M.D. Anderson in Houston who has been publicly questioning, in letters, papers, and The Cancer Letter, work by Potti et. al. … Continue reading The Importance of Being Reproducible: Keith Baggerly tells the Anil Potti story